NASDAQ
21.53USD
0.00 (0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
-1.75
52W range
5.635-21.53
Day range
21.53–21.53
Open
21.53
Prev close
21.53
Volume
0
Avg volume
4M
Dividend
0.00
IPO
2021-05-27
https://www.prnewswire.com/news-releases/are-wsr-tern-rlyb-dawn-obtaining-fair-deals-for-their-shareholders-302738642.html · 4/9/2026-0.30
https://www.etftrends.com/etf-building-blocks-content-hub/biotech-ma-spree-helps-lead-sbio-march-gains/ · 4/8/2026+0.90
https://www.businesswire.com/news/home/20260326808219/en/Day-One-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Day-One-Biopharmaceuticals-Inc.---DAWN/ · 3/26/2026-0.20
https://www.fool.com/coverage/stock-market-today/2026/03/06/stock-market-today-march-6-energy-stocks-rise-as-oil-closes-over-usd90-on-middle-east-tensions/ · 3/6/2026+1.00
https://www.globenewswire.com/news-release/2026/03/06/3251033/0/en/Servier-and-Day-One-Biopharmaceuticals-announce-acquisition-to-expand-Servier-s-rare-oncology-portfolio.html · 3/6/2026+1.00
https://www.globenewswire.com/news-release/2026/02/24/3244006/0/en/Day-One-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Reaffirms-2026-Outlook-and-Revenue-Guidance.html · 2/24/2026+0.80
https://www.zacks.com/stock/news/2827117/wall-street-analysts-see-a-101-08-upside-in-day-one-biopharmaceuticals-dawn-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2827117 · 2/2/2026+0.80
https://www.zacks.com/stock/news/2821738/strength-seen-in-zealand-pharma-as-zldpf-can-its-6-8-jump-turn-into-more-strength?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2821738 · 1/23/2026+0.60
https://www.globenewswire.com/news-release/2026/01/11/3216499/0/en/Day-One-Announces-Preliminary-2025-OJEMDA-Net-Product-Revenue-And-Provides-2026-Net-Product-Revenue-Guidance.html · 1/11/2026+0.90
https://www.newsfilecorp.com/release/276552/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Cadence-Bank-CADE · 12/1/2025-0.40
https://www.benzinga.com/m-a/25/11/48836647/day-one-biopharma-expands-oncology-pipeline-with-285-million-mersana-buyout · 11/13/2025+0.40
https://www.zacks.com/stock/news/2781502/wall-street-analysts-see-a-234-66-upside-in-day-one-biopharmaceuticals-dawn-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2781502 · 10/30/2025+0.80
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
